Heterogeneity in refractory acute myeloid leukemia

Area of Science:

• Hematology
• Genomics
• Oncology

Background:

• Achieving clinical remission is crucial for long-term survival in acute myeloid leukemia (AML).
• Up to 40% of AML patients exhibit refractory disease, characterized by poorly understood biology and poor prognosis.
• Limited knowledge of chemotherapy resistance mechanisms hinders the development of effective AML treatments.

Purpose of the Study:

• To identify distinct molecular subtypes within treatment-naive AML patient populations.
• To develop a prognostic classifier for chemorefractory AML based on gene expression.
• To explore group-specific therapeutic vulnerabilities in refractory AML.

Main Methods:

• Transcriptomic analysis of 154 treatment-naive AML cases.
• Development and validation of a four-gene refractory signature (RG4) classifier.
• Ex vivo drug sensitivity testing using 122 small-molecule inhibitors.

Main Results:

• Three distinct chemorefractory AML patient groups with unique expression profiles were identified.
• The RG4 classifier demonstrated prognostic value for overall survival (OS) and refined existing stemness scores.
• Differential pathway expression (cell cycle, transcription, metabolism, stemness) was observed in refractory subpopulations.
• Ex vivo drug screening revealed group-specific targeting opportunities for refractory AML.

Conclusions:

• Gene expression profiling can risk-stratify AML patients for OS and identify potential responders to alternative therapies.
• The RG4 classifier aids in understanding AML chemoresistance heterogeneity.
• Personalized therapeutic strategies targeting specific refractory AML subpopulations warrant prospective clinical investigation.